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ABSTRACT
Bisphosphonate doses used in cancer treatment are substantially higher than those used for osteoporosis. Little is known about the
effects of these high doses on tissue-level remodeling suppression. The aim of this study was to assess the effects of cancer dosing
regimens of zoledronic acid on tissue-level bone remodeling at different skeletal sites. Skeletally mature female beagle dogs were
treated with monthly intravenous infusions of vehicle (VEH, saline) or zoledronic acid (ZOL, 0.067mg/kg); an additional group of animals
was treated daily with oral alendronate (ALN, 0.2mg/kg/day). Doses of ZOL and ALN were, on a milligram per kilogram basis, consistent
with those used for cancer and osteoporosis, respectively. Following either 3 or 6 months of treatment, animals were euthanized, and
mandible, rib, and tibia were processed for dynamic bone histology. There was no evidence of oral lesions or bone matrix necrosis in the
mandibles of any animals. After 3 months, the rate of intracortical bone remodeling in the mandible was significantly suppressed with
ZOL ( 95%) compared with VEH; by 6 months, ZOL had produced nearly complete suppression ( 99%) compared with VEH. ZOL also
significantly suppressed remodeling in the rib cortex at both 3 ( 83%) and 6 ( 85%) months compared with VEH; tibia cortex bone
formation rate was nonsignificantly lower with ZOL treatment ( 68% to  75%). Remodeling suppression in ZOL-treated animals was
significantly greater than in ALN-treated animals at both the mandible and the rib; ALN and VEH were not different for any of the
assessed parametersatanyofthe sites. Compared across skeletalsites, the absolutelevel ofremodeling suppressionwith ZOLtreatment
was significantly greater at sites with higher remodeling, whereas the percent reduction was similar among the sites. These results
document nearly complete intracortical remodeling suppression resulting from monthly intravenous zoledronic acid dosing, with
changes being most dramatic at the mandible.  2010 American Society for Bone and Mineral Research.
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Introduction
S
ince first approved for treating malignant hypercalcemia,
bisphosphonates (BPs) have emerged as the gold standard
treatment for a number of metabolic bone diseases. The over-
whelming majority of BP prescriptions are written for post-
menopausal osteoporosis,
(1) yet BPs have become a standard
component of treatment/prevention for malignant hypercalce-
mia and bone metastases in cancer patients.
(2) In all these clinical
settings, BPs exert their skeletal effect by reducing bone
remodeling.
(1,3,4)
The emergence of bisphosphonate-related osteonecrosis of
the jaw (BRONJ) has raised concern about BPs, although a clear
cause-and-effect relationship has yet to be established between
BPs and BRONJ.
(5) Most BRONJ cases have manifested in patients
administered high doses of intravenous BPs for treatment/
prevention of cancer-related malignancies,
(6–9) with a smaller
number of cases reported in patients receiving oral BPs for
treatment of postmenopausal osteoporosis.
(5,9,10) While the
underlying pathophysiology of BRONJ remains unclear, most
hypotheses implicate remodeling suppression as an underlying
tissue-level mechanism
(11–14) because remodeling rates of the
mandible have been shown to exceed those of other cortical
bone sites.
(15–17)
Serum/urine biomarkers, measures of systemic bone remodel-
ing, have been studied in several cohorts of cancer patients
treated with BPs.
(18) These studies have shown that zoledronic
acid, administered at a dose of 4mg as an intravenous infusion,
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98significantly reduces bone remodeling by up to 80%.
(19–22) While
no head-to-head comparison exists, these systemic levels of
remodeling suppression with cancer doses of zoledronic acid are
similar in magnitude to those achieved with BP doses used for
osteoporosis, either yearly intravenous zoledronic acid
(23) or
more frequent doses of oral alendronate or risedronate.
(24,25)
One limitation to systemic markers of bone remodeling is their
lack of site specificity, because for a given biomarker level, the
rateofboneremodelingassessedhistologicallycandiffer10-fold
across various skeletal sites.
(26) Histologic assessment of bone
remodelinghasbeenconductedinseveralpreclinicalandclinical
studies associated with BP treatment for osteoporosis, yet few
data exist for BP doses used in cancer treatment.
The objective of this study was to determine the effect of
cancer doses of zoledronic acid administered as monthly
intravenous infusions on tissue-level bone remodeling using a
beagle dog model. Specifically, our focus was on change to
intracortical bone remodeling of the mandible, although other
skeletal sites, namely, the rib and the tibia, also were examined.
As a comparison tothe cancerdose of zoledronic acid, additional
animals were treated with a daily oral dose of alendronate to
mimic treatment used for postmenopausal osteoporosis. Our
hypothesis was that monthly intravenous zoledronic acid would
significantly suppress intracortical remodeling at all skeletal sites
compared with both vehicle- and alendronate-treated animals.
Methods
Animals
All experimental procedures were approved by the Indiana
University School of Medicine Institutional Animal Care and Use
Committee prior to the start of the study. Sixty skeletally mature
female beagles (1 to 2 years old) were purchased from Marshall
Farms USA (North Rose, NY). Animals were housed two per cage
inenvironmentallycontrolledrooms atIndianaUniversity School
of Medicine’s Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC)–accredited facility.
Experimental design
Following 1 week of acclimatization, animals were assigned to
one of three treatment groups (n¼20/treatment). Dogs were
treated with either monthly intravenous infusion of vehicle (VEH,
saline) or zoledronic acid (ZOL) or with daily oral dosing of
alendronate (ALN, Sigma-Aldrich). ZOL was administered at a
dose of 0.067mg/kg, which corresponds to the 4mg dose used
in cancer patients adjusted on a milligram per kilogram basis.
(27)
Zoledronic acid dissolved in saline (ZOL) or saline alone (VEH)
was administered in a 40mL volume via an over-the-needle
catheter (20-guage) in the cephalic vein. Infusions took place
overa15-minuteperiodinaccordancewithpreviouslypublished
protocols.
(28) For intravenous infusions of ZOL or VEH, animals
were sedated using 0.15mL Domitor (medetomidine, 1mg/mL),
which then was reversed with 0.2mL Antisedan IM (atipamezole,
5mg/mL) at the end of the infusion period. ALN was
administered at a dose of 0.20mg/kg per day, equivalent (on
a milligram per kilogram basis) to the 10mg dose used for
postmenopausal osteoporosis.
(29,30) This dose has been shown
previously to significantly suppress trabecular bone remodeling
in a beagle dog model by 71% within a year.
(31) ALN was
dissolved in saline and administered to the dogs orally with a
syringe each morning after an overnight fast and at least 2 hours
prior to feeding.
Animals in the three groups were treated for either 3 months
(n¼10/treatment) or 6 months (n¼10/treatment). Prior to
necropsy, animals were injected with calcein (0.20mL/kg IV)
using a 2-12-2-5 labeling schedule, meaning that label was
injected on 2 consecutive days, 12 days were allowed to pass,
another2consecutivedaysoflabelweregiven,andthenanimals
were euthanized 5 days later Animals were euthanized by
intravenous administration of sodium pentobarbital (Beuthana-
sia-D Special, 0.22mg/kg). After death, the right hemimandbile,
right ninth rib, and right tibia were dissected free and stored in
70% ethanol.
Histologic processing
A portion of the mandible ( 5mm) near the second molar
region (Fig. 1) was segmented by making parallel buccal-lingual
cuts using a band saw with a diamond-coated blade while under
constant irrigation. A 5mm segment of the rib (located at the
spotofgreatestcurvature)anda5mmsegmentofthedistaltibia
(4cm proximal to the distal end) also were prepared.
Tissues were stained with basic fuchsin in order to assess bone
matrixnecrosis.
(17)Using1%basicfuchsindissolvedinincreasing
concentrations of ethanol, specimens were stained according to
the following schedule: 48 hours in 80% (with one change to
fresh 80% solution after 24 hours), 48 hours in 95% (with one
change to fresh 95% solution after 24 hours), and 48 hours in
100% (with one change to fresh 100% solution after 24 hours).
Bones were placed under vacuum (20 in Hg) for all stages.
Calcein labeling can be clearly observed in fuchsin-stained
tissue.
(17)
Fig. 1. Photograph and DXA images depicting the second molar region,
at which dynamic histologic analyses were conducted.
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ethanol for 10 minutes and then placed in 100% methyl
methacrylate (MMA, Aldrich). Specimens then were transferred
to a solution of MMAþ3% dibutyl phthalate (DBP, Sigma-
Aldrich) for 3 to 7 days under vacuum and then embedded
using MMAþDBPþ0.25% catalyst (Perkadox 16
3, Akzo Nobel
Chemicals). Sections (80 to 100mm) from each bone segment
were cut in a cross-sectional plane by making parallel buccal-
lingual cuts using a diamond wire saw (Histosaw, Delaware
Diamond Knives).
Histologic assessment
Histologic measurements were made using a semiautomatic
analysis system (Bioquant OSTEO 7.20.10, Bioquant Image
Analysis Co.) attached to a microscope (Nikon Optiphot 2
microscope, Nikon) with a fluorescent light source. For most
skeletal sites, a single cross section was assessed for intracortical
bone formation rate. One exception was the 6-month ZOL-
treated animals, in which in the assessment of a single mandible
section from the 10 animals, only one osteon was found. Three
additional sections, one additional section from the second
molar region and two sections from the fourth premolar region
of the mandible, were analyzed in these animals to increase the
sampling region; therefore, data for the 6-month ZOL-treated
mandible represent four sections. We also assessed a second
region of the mandible (near the fourth premolar) of 6-month
VEH- and ALN-treated animals to determine if changes at the
second molar region were representative of the mandible at
large. All slides were blinded to treatment during analyses. For
mandible sections, data were collected separately for alveolar
bone regions (defined as bone above the most distally observed
portion of the tooth root) and nonalveolar bone regions (the
remainder of the tissue).
(17) The cortical bone of the entire cross
section of the rib and tibia was assessed. Under ultraviolet light,
the bone area (B.Ar.), number of labeled osteons (L.Os.#, osteons
with either single or double label), the total length of osteonal
labeled surface (L.S.), and the mean interlabel distance (Ir.L.Dis.)
were measured. For L.S., all label within osteons was measured
such that if an osteon had double label, the length of each was
measured.Mineralappositionrate(MAR,mm/day)wascalculated
as Ir.L.Dis./12, where 12 is the number of days between labels.
Intracortical bone formation rate (%/year) was calculated as
[MAR (L.S./2)/B.Ar. 100] 365. If a particular site for a given
animal had single-labeled osteons but no double-labeled
osteons, a value of 0.3 was used for MAR.
(32) If no label was
present, indicative of no active formation during the period of
assessment, MAR was considered to be a missing value. In these
cases, rather than use a missing value for bone formation rate
(BFR), which necessitates MAR for calculation, we have
considered BFR to be 0 so as to reflect the absence of bone
formation activity. All measures and calculations were in
accordance with American Society for Bone and Mineral
Research (ASBMR)–recommended standards.
(33)
Bone matrix necrosis in the mandible was assessed by bright-
fieldmicroscopy, asdescribedpreviously.
(17)Regions ofbonevoid
of basic fuchsin stain larger than 500mm
2 were considered
necrotic. For all animals, four complete cross sections of the
mandible from two different regions (second molar and fourth
premolar) were assessed for matrix necrosis.
Statistics
Statistical tests were performed using SAS software (SAS
Institute, Inc.). Differences among the three treatment groups
within each time point (3 or 6 months) were evaluated using a
one-way analysis of variance (ANOVA). When a significant overall
F value (p<.05) was noted, differences between individual
group means were compared using Fisher’s protected least-
significant-difference (PLSD) post hoc test. To determine the
relative effect of ZOL across the four skeletal sites (i.e., alveolar
mandible, nonalveolar mandible, rib, and tibia), absolute and
percent differences in BFR for each ZOL-treated animal were
calculated using the average values of the VEH animals at each
site.Thiswasdoneseparatelyforthe3-and6-monthtimepoints.
These absolute and percent differences were compared across
skeletal sites using a one-way ANOVA with repeated measures,
with PLSD post hoc tests used to compare individual group
means. For all tests, p .05 was considered significant.
Results
There was no difference among group body masses at baseline
orattheconclusionofthe3or6monthsoftreatment.Allanimals
completed the 3 or 6 months of treatment without complication,
and there was no evidence of oral lesions in any dog during the
study. There was no evidence of any bone matrix necrosis,
assessed by basic fuchsin staining, in the mandibles of any
animal after either 3 or 6 months of treatment.
Following 3 months of treatment, ZOL significantly reduced
intracortical bone remodeling of the mandible (Fig. 2A).
Compared with VEH, ZOL-treated animals had 95% lower
intracortical BFR in both the alveolar and nonalveolar portions of
the mandible (both p<.05). This lower turnover rate with ZOL
treatment was the result of fewer active sites (labeled osteons)
and a lower MAR compared with VEH (Table 1). ALN did not
significantly suppress intracortical BFR, labeled osteon number,
or MAR in either region of the mandible compared with VEH.
After 6 months of treatment, ZOL-treated animals had near-
complete suppression of BFR in the alveolar ( 99%) and
nonalveolar ( 99%) mandible compared with VEH-treated
controls (see Fig. 2B). As with the 3-month animals, this lower
turnover rate after 6 months of ZOL treatment was the result of
fewer active sites (labeled osteons) and a lower MAR compared
with VEH (see Table 1). ALN-treated animals did not differ from
VEH-treated animals for any of the mandible parameters at
6 months.
Analyses of a second region of the mandible (fourth premolar)
in 6-month VEH- and ALN-treated animals were consistent with
our analyses of the second molar region described earlier, both
in absolute terms and in comparisons among groups. In the
second molar region, 6-month VEH-treated animals had a mean
alveolar mandibular MAR of 2.24mm/day and a mean alveolar
BFR of 20.9%/year (see Fig. 2B and Table 1). At the fourth
premolar region, the mean alveolar MAR was 2.18mm/day, and
the mean alveolar BFR was 19.1%/year in VEH-treated animals;
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(p>.50). Furthermore, the effect of ALN also was consistent
betweenthe tworegions ofthe mandible, withthe secondmolar
region showing a 21% lower MAR and 39% lower BFR with ALN
treatment compared with VEH (see Fig. 2B and Table 1); the
fourth premolar region showed an 18% lower MAR and 43%
lower BFR with ALN treatment.
The effects of ZOL treatment on the rib were consistent with
those of the mandible. Compared with VEH, ZOL significantly
suppressed intracortical BFR by 83% (3 months) and 85% (6
months) (Fig. 3A,B). This lower BFR was the result of fewer active
sites (labeledosteons) andMAR compared withVEHatboth time
points (see Table 1). ALN did not significantly alter intracortical
BFR, labeled osteon number, or MAR of the rib at 3 months but
resulted in significantly fewer labeled osteons ( 46%) compared
with VEH by 6 months. Tibial intracortical BFR was nonsignifi-
cantly lower at 3 months ( 75%) and 6 months ( 68%) in ZOL-
treated animals compared with VEH (Fig. 3C,D), whereas there
was no effect of ALN at this site (see Fig. 3 and Table 1).
The absolute suppression of intracortical bone formation rate
with ZOLtreatmentsignificantly differed amongthefour skeletal
sites (Fig. 4). After 3 months of ZOL treatment, the absolute
reduction in BFR compared with VEH treatment was significantly
different at each of the four sites, with the effect at the alveolar
mandible > rib > nonalveolar mandible > tibia. After 6 months
of ZOL treatment, there was a nonsignificant difference in the
suppression of intracortical BFR in the alveolar mandible and rib
(p¼.06), whereas both those sites had significantly greater
suppression of remodeling than the nonalveolar mandible and
tibia. When expressed at a percentage of VEH-treated animals,
the effect of ZOL did not significantly differ among the four sites
at 3 months (p¼.23) or 6 months (p¼.20).
Discussion
In humans and other large animal species, cortical bone un-
dergoes remodeling within the cortex.
(34) Intracortical remodel-
Table 1. Intracortical Turnover Properties of Mandible, Rib, and Tibia
3 months 6 months
VEH ALN ZOL VEH ALN ZOL
Alveolar Mandible
Labeled osteon number, #/mm
2 1.33 0.31 0.88 0.25 0.10 0.04
 ,# 0.89 0.12 0.65 0.17 0.009 0.004
 ,#
Mineral apposition rate, mm/day 2.16 0.16 1.97 0.09 1.38 0.23
 ,# 2.24 0.16 1.78 0.32 0.30 0
 ,#
Non-Alveolar Mandible
Labeled osteon number, #/mm
2 0.50 0.13 0.46 0.09 0.09 0.05
 ,# 0.46 0.07 0.39 0.13 0.014 0.005
 ,#
Mineral apposition rate, mm/day 1.97 0.08 1.91 0.18 1.05 0.25
 ,# 1.81 0.26 1.81 0.21 0.30 0
 ,#
Rib
Labeled osteon number, #/mm
2 2.23 0.56 2.45 0.41 0.58 0.13
 ,# 1.94 0.39 1.04 0.19
  0.35 0.12
 
Mineral apposition rate, mm/day 1.24 0.14 1.45 0.06 0.83 0.19
# 1.68 0.11 1.26 0.29 1.08 0.28
 
Tibia
Labeled osteon number, #/mm
2 0.20 0.07 0.23 0.09 0.04 0.01 0.22 0.05 0.22 0.07 0.07 0.04
Mineral apposition rate, mm/day 1.15 0.24 1.95 1.06 1.04 0.25 1.56 0.18 1.31 0.27 1.09 0.33
Data presented as mean SE.
 p<0.05 versus VEH.
#p<0.05 versus ALN.
Fig. 2. Intracortical bone formation rate of the mandible. (A) After 3 months, animals treated with monthly intravenous zoledronic acid (ZOL) had
significantly a lower BFR in the alveolar and nonalveolar regions of the mandible compared with vehicle-treated controls (VEH); alveolar rates in ZOL-
treated animals also were significantly lower than in alendronate-treated animals (ALN). (B) After 6 months, ZOL treatment produced near-complete
suppressionofboneformationrateinbothalveolarandnonalveolarregions.ValuesabovebarsrepresentpercentageofvaluecomparedwithVEH-treated
animals within time point and region. p<.05 versus VEH ( ) or ALN (#). Data presented as mean SE.
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bone tissue that contains microdamage or that becomes
nonviable.
(35,36) We and others have documented the re-
modeling suppressive effects of BP treatment on intracortical
remodeling at various skeletal sites,
(26,37–42) including the
mandible.
(17) Following 3 years of daily oral alendronate, at a
dose five times higher than that used in the current study,
intracorticalboneformationinthealveolar boneofthemandible
in beagle dogs was significantly lower ( 84%) than in vehicle-
treated animals.
(17) At a dose consistent with that used clinically
for osteoporosis treatment and identical to that used in the
current report, alveolar remodeling was nonsignificantly lower
than vehicle ( 67%) after 3 years.
(17) These previous results,
combined with the current study, illustrate that suppression of
mandibular remodeling with osteoporosis dosing regimens
(specifically daily oral alendronate) is modest and has a relatively
slow onset. Conversely, the changes to intracortical bone
remodelingwithintravenouszoledronic acid,atdosesconsistent
with those used in cancer patients, are severe and rapid.
Mandibular remodeling was suppressed by 95% after 3 months
and 99% after 6 months of zoledronic acid. These data highlight
distinct differences in tissue-level remodeling suppression of the
mandible (as well as the rib and tibia) resulting from BP
treatment regimens used for osteoporosis (daily oral alendro-
nate) and cancer (monthly intravenous zoledronic acid).
The mechanism for differences in the remodeling suppression
profiles of these two treatment regimens are likely multifactorial.
The binding affinity of zoledronic acid is higher than that of
alendronate, meaning that zoledronic acid has a greater
attraction for and stronger attachment to mineral surfaces.
(43,44)
This factor alone, however, is unlikely toaccount forthe dramatic
differences noted in this study. More likely it is the combination
of this higher affinity coupled with the dosing amount and route
that account for the effects of zoledronic acid on remodeling
suppression. There is a linear relationship between BP dose and
skeletaluptake,
(45) suggesting that cumulativedose could have a
significantimpactontheamountofdrugtowhichtheskeletonis
exposed.Additionally,skeletaluptakeofBPissignificantlyhigher
with intravenous dosing compared with oral dosing, even when
differences in bioavailability profiles between the two routes are
matched.
(46) These differences in mineral affinity and skeletal
uptake may explain the differential remodeling suppression
profiles with osteoporosis treatment versus cancer treatment
regimens.
While there wasnear-complete remodeling suppression ofthe
mandible with intravenous ZOL (reduced from >20%/year to
Fig. 3. Intracortical bone formation rate of the rib (A, B) and tibia (C, D).
(A) After 3 months, animals treated with monthly intravenous zoledronic
acid (ZOL) had a significantly lower BFR in the rib compared with vehicle-
(VEH) and alendronate-treated (ALN) animals. (B) After 6 months, animals
treated with ZOL were significantly lower than VEH. (C, D). There was no
significant effect of ZOL or ALN treatments on intracortical BFR of the
tibia compared with VEH. Values above bars represent percentage of
value compared with VEH-treated animals within time point and region.
p<.05 versus VEH ( ) or ALN (#). Data presented as mean SE.
Fig. 4. Comparison of ZOL effect on intracortical remodeling suppres-
sion across the various bone sites of assessment. At both3 and 6 months,
the absolute reduction in intracortical BFR was determined relative to
VEH-treatedanimalsforthealveolarmandible, rib,nonalveolarmandible,
and tibia. Additionally, the percent reduction in intracortical BFR was
compared among the four sites at 3 and 6 months. Values represent
mean SE of the reduction in BFR compared with VEH. p<.05 versus
alveolar mandible ( ), rib (#), and nonalveolar mandible (y).
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remodeling at other cortical sites. Comparison of the effects of
ZOL on BFR across the four skeletal sites assessed show
significant site-specific effects on the absolute level of
intracortical bone formation suppression (Fig. 4). The effect of
ZOL is greatest in the alveolar portion of the mandible, followed
in order by the rib, nonalveolar mandible, and tibia. The
magnitudeofeffect,onanabsolutebasis,appearsintimatelytied
to the level of turnover in the untreated condition because the
BFR in VEH animals showed alveolar mandible > rib >
nonalveolar mandible > tibia. This is consistent with previous
analyses in our lab, which showed that the absolute level of
turnover suppression with BP treatment is related to the basal
turnover rate.
(47)
These data highlight the need for caution in generalizing
changesinboneremodelingobservedusingsystemicbiomarkers.
Clinical studies have shown similar degrees of remodeling
suppression with BP regimens used for cancer
(19–22) and
osteoporosis.
(23–25) Systemic biomarkers were not measured in
the current study, yet previous reports using doses of intravenous
zoledronicacidthatwerefourtimeshigherthanthoseusedinthis
studyhaveshownsuppressionofurinecross-linkedN-telopeptide
oftypeI collagen(NTX) byapproximately75% inbothnormal and
tumor-bearing dogs.
(28,48) Assuming that biomarker levels of
remodeling would be similar in the current ZOL-treated animals,
this emphasizes that such biomarker measures, while quite useful
on a systemic basis, have limitations with respect to knowing
effects of treatment on specific skeletal sites. Given that the
percent reduction in BFR with ZOL among the skeletal sites was
not significantly different (see Fig. 4), it is possible that histologic
measures of bone remodeling at one site, such as the iliac crest,
cangivesomeinsightintothemagnitudeofeffectthroughoutthe
skeleton.
The differential effects of remodeling suppression between BP
dosing for osteoporosis and cancer have clear relevance for BP-
related osteonecrosis of the jaw (BRONJ). The risk of BRONJ is
significantly greater and the mean time to onset is shorter in
cancer patients compared with those treated with these drugs
for osteoporosis.
(5) The current report is consistent with these
clinical data, showingthat following the initiation oftreatment (3
to 6 months), the level of remodeling suppression is more severe
with intravenous zoledronic acid than with oral alendronate.
Whether or not the speed of onset or degree of remodeling
suppression plays a role in the pathophysiology of BRONJ
remains to be determined.
We have shown previously that suppression of intracortical
remodeling following 3 years of oral alendronate treatment is
associated with the accumulation of nonviable bone matrix,
defined as an absence of osteocytes and nonpatent canaliculi.
(17)
This finding has led us to hypothesize that focal regions of
osteocytes become nonviable, and these regions are unable to
be remodeled sufficiently owing to the effects of BPs.
(17) There
were no regions of bone matrix necrosis in the mandibles of any
animals in this study. This suggests, not unexpectedly, that the
development of these regions, which involves filling in of the
canalicular network with mineral, takes time. Thus, even though
remodeling of the mandible is significantly suppressed within
the first 3 months with zoledronate at cancer doses, it appears to
take greater than 6 months for the development of matrix
necrosis.
Recently, we have reported that trabecular bone appears to
have a lower limit of suppression with BP treatment,
(47)
interpreted as evidence against the theory of remodeling
oversuppression.
(49,50) Current data suggest that our earlier
report may be limited to trabecular bone or to alendronate
treatment because the level of intracortical remodeling
suppression with intravenous ZOL clearly can reach a nadir at
or close to zero at some skeletal sites. The dramatic effects of
cancer treatment doses of zoledronic acid on bone remodeling
in the mandible suggest the need to consider alternative doses
or dosing regimens in cancer patients. Clearly, the current study
does notaddressthe level ofremodelingthat isnecessary forthe
primary goal of such treatment regimens—to offset adverse
changes associated with the cancer itself. It is possible that
complete suppression of mandibular remodeling may be a
necessary consequence of successfully controlling the cancer-
induced changes. However, early clinical data suggest that such
large doses are not necessary for equivalent suppression of
remodeling, as assessed by biomarkers. Early work aimed at
controlling hypercalcemia of malignancy concluded that of
several zoledronic acid doses (0.002, 0.005, 0.01, 0.02, and
0.04mg/kg), the highest two doses (equating to 1.2 and 2.4mg,
respectively, for a 60mg person) provided superior control of
serum calcium compared with the others.
(51) Two subsequent
studies in which patients were treated with a single intravenous
dose of zoledronic acid (1, 2, 4, 8, or 16mg)
(52) or monthly
intravenous zoledronic acid (0.1, 0.2, 0.4, 0.8, 1.5, 2.4, or 8mg)
(19)
reached the conclusion that doses ofless than 1mg wereinferior
for suppression of remodeling biomarkers, yet doses between
1.5and16mgwereallcomparable.Whilefurtherstudiesshowed
that doses above 4mg result in renal safety issues,
(20) very little
work has been done on doses lower than 4mg despite the fact
that these data suggest the half this dose may be effective in this
patient population.
In conclusion, we show significant intracortical remodeling
suppression resulting from monthly intravenous zoledronic acid
dosing regimens analogous to those used in cancer patients.
These changes are more pronounced than those that occur with
dosing regimens used for osteoporosis (daily oral alendronate).
Most notable was the suppression imparted by zoledronic acid
on the mandible, where remodeling suppression was near
complete.
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